Relationship between proton-pump inhibitor USE and lower blood magnesium levels
Abstract
Objective: The aim of this study was to determine whether and to what degree proton-pump inhibitor (PPI) use affects blood magnesium levels.Methods: We performed a cross-sectional comparative study with consecutive sampling technique from June to October 2016. This study comparedblood magnesium levels of patients using PPIs (lansoprazole and omeprazole) with those of patients not taking PPIs. The total sample was 184 patients.Data collected included questionnaires and medical records. Statistical analysis was performed with the unpaired t-test, Mann–Whitney U-test, andone-way analysis of variance.Results: The average magnesium level in patients using PPIs was 2.08±0.21 mg/dL, whereas the average magnesium level in patients not using PPIswas 2.27±0.38 mg/dL, a statistically significant difference (p1 yearand in patients using omeprazole (p1 year. Thus, the long-term use of PPIs may lead to decreased levels ofmagnesium. Therefore, monitoring the levels of magnesium is important in patients using PPIs for a long term to avoid the risk of hypomagnesemia.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 184 participants or records.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.